For instance, olaparib, a clinically approved poly ADP ribose polymerase (PARP) inhibitor, has been demonstrated to induce 5hmC labeling loss, thereby inhibiting the proliferation of T‐ALL leukemia cells.[36] The role of TET1 in CCA has been the subject of several studies. This evidence concerns the gene TET1 and leukemia.